125 related articles for article (PubMed ID: 29149986)
1. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts.
Martín-Fernández M; Rubert M; Montero M; de la Piedra C
Transplant Proc; 2017 Nov; 49(9):2219-2224. PubMed ID: 29149986
[TBL] [Abstract][Full Text] [Related]
2. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S
Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat.
Thomson AW; Propper DJ; Woo J; Whiting PH; Milton JI; Macleod AM
Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):355-69. PubMed ID: 7693791
[TBL] [Abstract][Full Text] [Related]
4. The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand.
Shui C; Riggs BL; Khosla S
Calcif Tissue Int; 2002 Nov; 71(5):437-46. PubMed ID: 12202955
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus and tacrolimus rather than cyclosporine A cause bone loss in healthy adult male rats.
Rubert M; Montero M; Guede D; Caeiro JR; Martín-Fernández M; Díaz-Curiel M; de la Piedra C
Bone Rep; 2015 Jun; 2():74-81. PubMed ID: 28377957
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma.
Tory R; Sachs-Barrable K; Hill JS; Wasan KM
Int J Pharm; 2008 Jun; 358(1-2):219-23. PubMed ID: 18448283
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling.
Hafizi S; Mordi VN; Andersson KM; Chester AH; Yacoub MH
Vascul Pharmacol; 2004; 41(4-5):167-76. PubMed ID: 15607500
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes.
Cho ML; Kim WU; Min SY; Min DJ; Min JK; Lee SH; Park SH; Cho CS; Kim HY
Arthritis Rheum; 2002 Jan; 46(1):42-51. PubMed ID: 11817607
[TBL] [Abstract][Full Text] [Related]
10. Effects of tacrolimus, cyclosporin A and sirolimus on MG63 cells.
Krocker D; Perka C; Tuischer J; Funk J; Tohtz S; Buttgereit F; Matziolis G
Transpl Int; 2006 Jul; 19(7):563-9. PubMed ID: 16764635
[TBL] [Abstract][Full Text] [Related]
11. Novel apoptosis assay to analyze immunosuppression.
Boldt A; Barten MJ; Weiss C; Sagner A; Mohr FW; Gummert JF
Cytometry A; 2006 Mar; 69(3):158-60. PubMed ID: 16479615
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro.
Liu C; Schreiter T; Frilling A; Dahmen U; Broelsch CE; Gerken G; Treichel U
World J Gastroenterol; 2005 Dec; 11(48):7602-5. PubMed ID: 16437685
[TBL] [Abstract][Full Text] [Related]
13. A novel library screen identifies immunosuppressors that promote osteoblast differentiation.
Darcy A; Meltzer M; Miller J; Lee S; Chappell S; Ver Donck K; Montano M
Bone; 2012 Jun; 50(6):1294-303. PubMed ID: 22421346
[TBL] [Abstract][Full Text] [Related]
14. Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats.
Charoenphandhu N; Teerapornpuntakit J; Methawasin M; Wongdee K; Thongchote K; Krishnamra N
Can J Physiol Pharmacol; 2008 May; 86(5):240-8. PubMed ID: 18432284
[TBL] [Abstract][Full Text] [Related]
15. [Adiponectin regulates the expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand in human osteoblast].
Zhang XM; Xie H; Yuan LQ; Luo XH; Liao EY
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(22):1562-5. PubMed ID: 18956641
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus.
Khanna AK
Transplantation; 2000 Aug; 70(4):690-4. PubMed ID: 10972232
[TBL] [Abstract][Full Text] [Related]
17. Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A.
Ko H; Hambly BD; Eris JM; Levidiotis V; Wyburn K; Wu H; Chadban SJ; Yin JL
Transpl Immunol; 2008 Nov; 20(1-2):99-105. PubMed ID: 18662782
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine A, but not tacrolimus, is associated with impaired proliferation and differentiation of human osteoblast-like cells in vitro.
Moreira RO; Thiago LS; Oliveira FL; Balduino A; Borojevic R; Duarte ME; Farias ML
Med Sci Monit; 2009 Mar; 15(3):BR65-70. PubMed ID: 19247234
[TBL] [Abstract][Full Text] [Related]
19. Transient receptor potential vanilloid-1 regulates osteoprotegerin/RANKL homeostasis in human periodontal ligament cells.
Sooampon S; Manokawinchoke J; Pavasant P
J Periodontal Res; 2013 Feb; 48(1):22-9. PubMed ID: 22587561
[TBL] [Abstract][Full Text] [Related]
20. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.
Giner M; Rios MJ; Montoya MJ; Vázquez MA; Miranda C; Pérez-Cano R
Eur J Pharmacol; 2011 Jan; 650(2-3):682-7. PubMed ID: 21050847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
